Edgar Filing: BRYCE RICHARD PAUL - Form 4

BRYCE RICH Form 4											
January 24, 20	Л								OMB AF	PROVAL	
Check this	Washington, D.C. 20549									3235-0287 January 31,	
if no longer subject to Section 16. Form 4 or	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF								Expires: 20 Estimated average burden hours per response		
Form 5 obligations may contin <i>See</i> Instruct 1(b).	ue. Section 1	7(a) of the		lity Holdi	ng Com	pany	Act of	Act of 1934, 1935 or Section)	1		
(Print or Type Re	sponses)										
BRYCE RICHARD PAUL Symb PUM				2. Issuer Name and Ticker or Trading ymbol UMA BIOTECHNOLOGY, INC. PBYI]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 3. Date (Mont				ate of Earliest Transaction nth/Day/Year) 22/2019				Director 10% Owner X_Officer (give title Other (specify below) SEE REMARKS			
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
LOS ANGEL	ES, CA 9002	4						Form filed by M Person	ore than One Re	porting	
(City)	(State)	(Zip)	Table	I - Non-De	rivative S	ecurit	ies Acqu	iired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction (Month/Day/Y	ear) Execut any		Code (Instr. 8)	4. Securi or(A) or D (Instr. 3,	ispose 4 and (A) or	d of (D)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
COMMON STOCK	01/22/2019			S <u>(1)</u>	1,959	D	\$ 24.72	29,374	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: BRYCE RICHARD PAUL - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
BRYCE RICHARD PAUL							
C/O PUMA BIOTECHNOLOGY, INC.			SEE				
10880 WILSHIRE BLVD., SUITE 2150			REMARKS				
LOS ANGELES, CA 90024							

Signatures

/s/ Richard Paul 01/24/2019 Bryce

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 19, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units.

Remarks:

Title of Reporting Person: Chief Medical and Scientific Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.